The announcement of additional data demonstrating the long-term benefits of Barostim in treating heart failure patients with reduced ejection fraction is likely to be viewed positively by investors. It not only validates the effectiveness of Barostim but also suggests a sustained market demand and potential revenue growth for CVRx. This could lead to increased investor confidence and a positive impact on CVRx's stock price in the short term.